Skip to main content
SpringerLink
Log in

Assessing Treatment Results for Benign Prostatic Hyperplasia

  • Chapter
Alternate Methods in the Treatment of Benign Prostatic Hyperplasia

Abstract

Nowhere in urology has the philosophy of treatment for a particular disease, or the list of options for treatment, changed so markedly over a short period of time as it has for benign prostatic hyperplasia (BPH). In 1985, in the second tome on BPH published by the National Institutes of Health (NIH), following an NIH sponsored conference on the subject, Frank Hinman, Jr. expressed the prevailing philosophy, at least among urologists, regarding the treatment of BPH: “Men will choose between continuing medical therapy for the rest of their lives or having a one time operation” (Hinman 1985). At that time, a short 7 years ago, the “medical therapy” consisted only of side effect producing means of decreasing serum testosterone or interfering with its action and nonselective α-adrenergic blockade. A tabulation of the treatment options for BPH now available is seen in Table 1, a list that will probably be incomplete by the time of publication of this volume. Lest one think this is a “pie in the sky” list, only two of these options (growth factor inhibitor and pyrotherapy) could be listed as laboratory, experimental, or theoretical considerations, while the rest are in fact real and available options, most of which are being vigorously pursued by one or another commercial company. At the 1992 meeting of the American Urological Association (AUA), there were two courses on balloon dilatation, one course on the pharmacology of BPH, one course on nonsurgical management of BPH, one course on new nonmedical trends in the management of BPH, and one course on hyperthermia!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrams PH (1977) A double blind trial of the effects of candicidin on patients with benign prostatic hypertropy. Br J Urol 53:613

    Google Scholar 

  • Abrams P (1985) Detrusor instability and bladder outlet obstruction. Neurourol Urodyn 4:317

    Article  Google Scholar 

  • Abrams PH, Griffiths DJ (1979) The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 51:129

    Article  PubMed  CAS  Google Scholar 

  • Anderson JT (1982) Prostatism: clinical, radiologic and urodynamic aspects. Neurourol Urodyn 1:241

    Article  Google Scholar 

  • Aso Y, Boccon-Gibod L, Colais DaSilva F, Chaussy C, Fowler J, Homma Y, Legrain M, Moriyama N, Richard F, Tazaki H (1991) Subjective response, objective response impact on quality of life. In: Cockett A, Aso Y, Chatelain et al. (eds) Proceedings of the international consultation on BPH, Digital Print, Ivry/Seine, France, 1991, pp 87–90

    Google Scholar 

  • Ball AJ, Feneley RCL, Abrams PH (1981) The natural history of untreated “prostatism”. Br J Urol 53:613

    Article  PubMed  CAS  Google Scholar 

  • Barry MJ, Mulley AG, Fowler FJ, Wennberg JW (1988) Watchful waiting versus immediate transurethral resection for symptomatic prostatism: the importance of patients’ perferences. JAMA 259:2010

    Article  Google Scholar 

  • Benson H, Epstein MD (1976) The placebo effect. JAMA 232:1225

    Article  Google Scholar 

  • Birch NC, Hurst G, Doyle PT (1988) Serial residual volumes in men with prostatic hypertrophy. Br J Urol 62:571

    Article  PubMed  CAS  Google Scholar 

  • Blaivas JG (1989) Evaluation of bladder outlet obstruction. In: Paulsen DF (ed) Prostatic disorders. Lea and Febiger, Philadelphia, pp 173–192

    Google Scholar 

  • Boyarsky S, Jones G, Paulson DF, Prout GR Jr (1977) A new look at bladder neck obstruction by the food and drug administration: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 68:29

    Google Scholar 

  • Bruskewitz RC, Iverson P, Madsen PO (1982) Value of postvoid residual urine determination in evaluation of prostatism. Urology 20:602

    Article  PubMed  CAS  Google Scholar 

  • Bruskewitz R, Jensen KME, Iversen P, Madsen PO (1983) The relevance of minimum urethral resistance in prostatism. J Urol 129:769

    PubMed  CAS  Google Scholar 

  • Claridge M (1983) Assessment of medical treatment. In: Hinman F Jr (ed) Benign Prostatic Hypertrophy. Springer, Berlin, Heidelberg New York, pp 308–312

    Chapter  Google Scholar 

  • Coolsaet B, Blok C (1986) Detrusor properties related to prostatism. Neurourol Urodyn 5:435

    Article  Google Scholar 

  • Dixon CM, Lepor H (1991) Transurethral dilatation of the prostate. Probl Urol 5(3):463

    Google Scholar 

  • Drach GW, Layton T, Bottaccini MR (1982) A method of adjustment of male peak urinary flow rate for varying age and volume voided. J Urol 128:960

    PubMed  CAS  Google Scholar 

  • Fingl E, Woodbury DM (1975) General principles. In: Goodman LS, Gilman A (eds) The pharmacologic basis of therapeutics. Macmillan, New York, pp 1–46

    Google Scholar 

  • Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D (1988) Symptom status and quality of life following prostatectomy. JAMA 259:3018

    Article  PubMed  Google Scholar 

  • Franks LM (1954) Benign hyperplasia of prostate. Ann Roy Coll Surg 14:92

    Google Scholar 

  • Friedman LM, Furberg CD, DeMetz DL (1981) Fundamentals of clinical trials. Wright, Boston, pp 69–88

    Google Scholar 

  • Geller J, Nelson CG, Pilbert JD, Pratt C (1979) Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy. Urology 14:467

    Article  PubMed  CAS  Google Scholar 

  • Graversen PH, Gasser TC, Wasson JH, Hinman F Jr, Bruskewitz RC (1989a) Controversies about indications for transurethral resection of the prostate. J Urol 141:475

    PubMed  CAS  Google Scholar 

  • Graversen PH, Bruskewitz RC, Madsen PO (1989b) The predictive value of urodynamic investigations for results following prostatectomy. In: Paulson DF (ed) Prostatic disorders, Lea and Febiger, Philadelphia, pp 232–245

    Google Scholar 

  • Greenfield S (1989) The state of outcome research: are we on target? NEJM 320:1142

    Article  PubMed  CAS  Google Scholar 

  • Haylen BT, Sabby D, Sutherst JR, Frazer MI, West CR (1989) Maximum and average urine flow rates in normal male and female populations-the Liverpool nomograms. Br J Urol 64:30

    Article  PubMed  CAS  Google Scholar 

  • Heyns CF, de Klerk DP (1989) Pharmaceutical management of benign prostatic hyperplasia. In: Paulson DF (ed) Prostatic disorders. Lea and Febiger, Philadelphia, pp 204–231

    Google Scholar 

  • Hinman F Jr (1983) Residual urine: measurement and influence in management of obstruction. In: Hinman F Jr (ed) Benign Prostatic Hypertrophy. Springer, Berlin Heidelberg New York, pp 589–596

    Chapter  Google Scholar 

  • Hinman, F., Jr. (1985) Overview — basis for clinical management, BPH, vol 2, NIH Publ 87-2881, Bethesda, p 205

    Google Scholar 

  • Jensen KME (1989) Clinical evaluation of routine urodynamic investigations in prostatism. Neurourol Urodyn 8:545

    Article  Google Scholar 

  • Jensen KME, Jorgensen JB, Magnesen P (1988) Urodynamics in prostatism: II. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol [Suppl] 114:72

    CAS  Google Scholar 

  • Kitada S, Ishisawa N (1981) Urethral pressure profilometry in the prospective assessment for prostatectomy. J Urol 126:89

    PubMed  CAS  Google Scholar 

  • Layton TM, Drach GW (1983) Urinary flow rates: measurement and adjustment. In: Hinman F Jr (ed) Benign Prostatic Hypertrophy. Springer, Berlin Heidelberg New York, pp 524–527

    Google Scholar 

  • Lebacqz K (1979) Controlled clinical trials: some ethical issues. Controlled Clin Trials 1:29

    Article  Google Scholar 

  • Lytton B, Emery JM, Howard BM (1968). The incidence of benign prostatic obstruction. J Urol 99:639

    PubMed  CAS  Google Scholar 

  • Madsen PO, Iversen P (1983) A point system for selecting operative candidates. In: Hinman F Jr (ed) Benign Prostatic Hypertrophy. Springer, Berlin Heidelberg New York, pp 763–765

    Chapter  Google Scholar 

  • Mebust W, Roizo R, Schroeder F, Villers A (1991) Correlations between pathology, clinical symptoms and the course of the disease. In: Cockett A, Aso Y, Chatelain B et al. (eds) Proceedings of the international consultation on BPH, digital print, Ivry/Seine, France, pp 53–62

    Google Scholar 

  • Peters CA, Walsh PC (1987) The effect of naferelin acetate, a leutinizing hormone releasing hormone agonist on benign prostatic hyperplasia. NEJM 317:599

    Article  PubMed  CAS  Google Scholar 

  • Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, Ramsey E (1989) Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. NEJM 320:1120

    Article  PubMed  CAS  Google Scholar 

  • Schafer W, Rubben H, Noppeney R, Deutz FJ (1989) Obstructed and unobstructed prostatic obstruction: a plea for urodynamic objectivation of bladder outflow obstruction in benign prostatic hyperplasia. World J Urol 6: 198

    Article  Google Scholar 

  • Siroky MB, Olsson CA, Krane RJ (1979) The flow rate nomogram: I. Development. J Urol 122:665

    PubMed  CAS  Google Scholar 

  • Siroky MB, Olsson CA, Krane RJ (1980) The flow rate nomogram: II. Clinical correlations. J Urol 123:208

    PubMed  CAS  Google Scholar 

  • Susset JG, Picker P, Kretz M, Jorest R (1973) Critical evaluation of uroflometers and analysis of normal curves. J Urol 109:874

    PubMed  CAS  Google Scholar 

  • Wein AJ (1981) Where are we: clinical trials. In: Zinner NR, Sterling AR (eds) Female incontinence, Liss, New York, pp 39–43

    Google Scholar 

  • Wein AJ (1983) Principles for evaluation of pharmacologic agents. In: Hinman F Jr (ed) Benign Prostatic Hypertrophy. Springer, Berlin Heidelberg New York, pp 414–418

    Chapter  Google Scholar 

  • Wein AJ (1990) Evaluation of treatment response to drugs in benign prostatic hyperplasia. Urol Clin North Am 17(3):631

    PubMed  CAS  Google Scholar 

  • Wein AJ, Barrett DM (1988) Voiding function and dysfunction: a logical and practical approach. Year Book Medical Publishers, Chicago, pp 278–280 a

    Google Scholar 

Download references

Authors
  1. A. J. Wein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, St. Luke’s/Roosevelt Hospital Center, 428 West 59th Street, New York, New York, 10019, USA

    Nicholas A. Romas M.D.

  2. New York Hospital-Cornell Medical Center, 525 East 68th Street, New York, New York, 10021, USA

    E. Darracott Vaughan M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wein, A.J. (1993). Assessing Treatment Results for Benign Prostatic Hyperplasia. In: Romas, N.A., Vaughan, E.D. (eds) Alternate Methods in the Treatment of Benign Prostatic Hyperplasia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45723-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-45723-4_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-45725-8

  • Online ISBN: 978-3-642-45723-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation